Polaryx Therapeutics CMO Lisa Bollinger resigns effective immediately

Polaryx Therapeutics, Inc.

CMO Lisa Bollinger, MD, resigned on July 19, 2026, effective immediately.
Company states resignation will not affect clinical timelines, regulatory plans, or development strategy.
Search for successor commenced; existing leadership team will assume CMO responsibilities in interim.

item 5.02

Polaryx Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-080041

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.